- Case Report
- Open Access
CA19-9-Producing early gastric adenocarcinoma arising in hyperplastic foveolar polyp: a very unique resection case
© Guo et al; licensee BioMed Central Ltd. 2011
- Received: 23 May 2011
- Accepted: 10 November 2011
- Published: 10 November 2011
Here we report the first case of carbohydrate antigen (CA) 19-9-producing early gastric adenocarcinoma arising in polyp. A solitary pedunculated polyp lesion of the stomach, measuring 26 × 20 × 20 mm, was noticed in a 76-year-old Japanese woman due to an abdominal disorder, associated with a markedly high serum CA19-9 level (2,172.6 U/ml). After endoscopic mucosal resection was performed, the CA19-9 level was drastically decreased and normalized. The scanning view of immunohistochemical staining of CA19-9 exhibited a focal, not diffuse, positive-expression in the hyperplastic epithelium and, especially, in the irregular and fused tubular glands and the mucinous material secreted into the dilated glands. In particular, microscopic examination of the strongly CA19-9-positive areas showed structurally atypical epithelium containing mildly to focal moderately enlarged nuclei and prominent nucleoli with loss of cellular polarity, estimated as adenocarcinoma. No stromal invasion was evident. Immunohistochemically, distinct nuclear stainings for p53 and Ki-67 were seen, occasionally conforming to the CA19-9-positive atypical cells, respectively, confirmed by double immunostaining. These hyperplastic and atypical cells were classified into the pure gastric phenotype by mucin histochemical methods. Based on these features, we finally made a conclusive diagnosis of CA19-9-producing in situ well differentiated adenocarcinoma of gastric type arising in hyperplastic foveolar polyp. We suggest that the markedly high serum CA 19-9 level could be indicative of carcinoma in polyp at the very least.
The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1692254825554310
- CA19-9-producing adenocarcinoma
- early cancer
- hyperplastic foveolar polyp
It is generally accepted that malignant transformation and progression in tumors are closely related to alterations in cell-surface carbohydrate antigens (CAs) with frequent aberrant glycosylation . CA19-9 is a sialylated-Lewisa blood group antigen which has been shown to be useful for monitoring malignant tumor status, including the invasive and/or metastatic behavior of carcioma cells affecting adhesion, motility or immunogenicity [2, 3]. Monoclonal antibody 19-9, derived from mice spleen cells immunized with human colon adenocarcinoma cell line SW1116, can detect its antigen in the serum of patients, mainly existing in mucins containing a sialylated lacto-N-fucopentaose II, IV3-α-NeuNAc-III4-α-Fuc-LcOse4, in which LcOse4 is Galβ1-3GlcNAcβ1-3Galβ1-4Glc [4, 5]. The existence of CA19-9-producing gastric cancer has been suggested, defined by three factors according to a Japanese report: first, the patients have high serum CA19-9 levels before resection; second, CA19-9 expression can be identified by using the CA19-9 antibody in the resected specimens; third, the serum CA19-9 levels are significantly decreased after resection . At least 28 cases of CA19-9-producing gastric cancer have been reported in the Japanese literature, but none in the English language literature . Here we report an extremely rare and the first case of a CA19-9-producing gastric adenocarcinoma arising in hyperplastic foveolar polyp.
It is well known that gastric hyperplastic polyps rarely demonstrate malignant transformation, the incidence of which is reported to be 0.8% to 4.5% [9, 10]. The characteristics of the adenocarcinoma arising in a hyperplastic polyp have been described as predominantly well differentiated histologic type, associated with intraepithelial neoplasia, gastric phenotype the same as a preexisting polyp, and a crucial role of p53 in malignant transformation [9, 11, 12]. Additionally, an increase in size is suggested to be a risk factor of malignancy . In the case of a larger polyp measuring more than 20 mm, the incidence of adenocarcinoma transformation has been significantly increased up to 5.0% to 8.2% [9, 13]. The carcinoma components are thought to arise in the surface of the polyp and extend or invade into the stalk side in a downward growth pattern . According to the immunohistochemical analyses in 22 lesions of epithelial neoplasia arising in gastric hyperplastic polyps by Yao et al., 73.0% of neoplastic components were still classified as gastric phenotype by using the same evaluation methods as the present study . As to p53, considered to be one of the most important gene products in various malignancies as well as gastric cancer, its overexpression was observed in neoplastic components associated with carcinogenesis in an early phase, whereas entirely negative in hyperplastic ones . Additionally, higher Ki-67 labeling index, useful for the evaluation of proliferative activity, were also recognized only in carcinoma components, similar to the present case . In this context, we believe that the current case best fits the category of carcinoma in polyp.
Surprisingly, the serum CA19-9 level before mucosal resection of the current polyp was much higher (more than 2,000 U/ml) than that after it. In addition, CA19-9 immunohistochemical expression was detected focally in this specimen. These features are consistent with CA19-9-producing gastric neoplasms, characteristics of which also are well differentiated and gastric foveolar phenotypes, but often poor prognosis with invasion depth beyond the submucosal layer . There are no previous reports of CA19-9-producing in situ gastric cancer or CA19-9-producing gastric cancer arising in polyp such as the present case. To date only 5 early gastric cancer cases out of 28 CA19-9-producing neoplasms have been reported, and interestingly, those serum CA19-9 levels before surgery were relatively low, less than 2,000 U/ml, unlike the current one . By contrast, little is clearly understood with regard to the mechanism by which CA19-9 antigens in mucins derived from gastrointestinal, colon, or pancreatic neoplasms transfer to vascular lumens. It has been reported that patients with acute cholangitis accompanied by cholestasis or with gastric ulcer after long-term administration of Sucralfate rarely have high serum CA19-9 levels [14, 15]. These phenomena thus suggest that any obstructive disorder between the digestive tract lumen and mucin-secreting epithelium could induce the CA19-9 antigens to compress into the blood. As shown in Figure 2 of the present case, CA19-9 was particularly expressed on the accumulated mucin in the cystically dilated glands, reminiscent of blockade of mucin secretion. Further investigation with more clinical samples is necessary to determine how and whether or not the high serum CA19-9 levels are correlated with pathological findings and immunohistochemical expression patterns of CA19-9. While, the tumor cells can secrete CA19-9 even when the turnover of it is too rapid to accumulate and express. It is thus possible that the expression pattern of CA19-9 immunoreactivity was little significance. Nevertheless, we assume that, the serum CA19-9 level of more than 2,000 U/ml in the present case could be indicative of malignant transformation at the very least, because overexpression of CA19-9 results from a clonal growth of abnormal cells having genetic and/or epigenetic disorders .
On the other hand, the rate of high serum CA19-9 levels before surgery among all patients with gastric cancer is not remarkable, only 25% to 30%, and thus, the serum CA19-9 levels are not clinically important for a tumor marker, but only for a prognosis indicator [3, 6, 14]. In that sense, since most clinicians have never examined the serum CA19-9 levels for merely gastric polyp lesions, CA19-9-producing gastric carcinoma in polyp may be more common than generally considered.
We herein reported the first case of a CA19-9-producing early well differentiated adenocarcinoma arising in gastric hyperplastic foveolar polyp. We should be aware that gastric polyp lesions might rarely produce markedly high CA19-9 antigens, possibly associated with malignant transformation.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Brockhausen I: Pathways of O-glycan biosynthesis in cancer cells. Biochim Biophys Acta. 1999, 1473: 67-95. 10.1016/S0304-4165(99)00170-1.View ArticlePubMedGoogle Scholar
- Kim YS, Itzkowitz SH, Yuan M, Chung Y, Satake K, Umeyama K, Hakomori S: Lex and Ley antigen expression in human pancreatic cancer. Cancer Res. 1988, 48: 475-482.PubMedGoogle Scholar
- Kochi M, Fujii M, Kanamori N, Kaiga T, Kawakami T, Aizaki K, Kasahara M, Mochizuki F, Kasakura Y, Yamagata M: Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer. Gastric Cancer. 2000, 3: 177-186. 10.1007/PL00011715.View ArticlePubMedGoogle Scholar
- Magnani JL, Nilsson B, Brockhaus M, Zopf D, Steplewski Z, Koprowski H, Ginsburg V: A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem. 1982, 257: 14365-14369.PubMedGoogle Scholar
- Magnani JL, Steplewski Z, Koprowski H, Ginsburg V: Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res. 1983, 43: 5489-5492.PubMedGoogle Scholar
- Aisu N, Hiroyoshi M, Ootsubo D, Nakamura Y, Yamamoto T, Nakai T: A CA19-9-producing gastric cancer. Nihon Rinsho Geka Gakkai Zasshi. 2010, 71: 683-689. 10.3919/jjsa.71.683. (in Japanese with English abstract)View ArticleGoogle Scholar
- Yamada T, Fukutomi H: Gastric elevated lesions. Stomach and Intestine (I to Cho). 1966, 1: 145-150. (in Japanese)Google Scholar
- Yao T, Kajiwara M, Kuroiwa S, Iwashita A, Oya M, Kabashima A, Tsuneyoshi M: Malignant transformation of gastric hyperplastic polyps: alteration of phenotypes, proliferative activity, and p53 expression. Hum Pathol. 2002, 33: 1016-1022. 10.1053/hupa.2002.126874.View ArticlePubMedGoogle Scholar
- Daibo M, Itabashi M, Hirota T: Malignant transformation of gastric hyperplastic polyps. Am J Gastroenterol. 1987, 82: 1016-1025.PubMedGoogle Scholar
- Morais DJ, Yamanaka A, Zeitune JM, Andreollo NA: Gastric polyps: a retrospective analysis of 26,000 digestive endoscopies. Arq Gastroenterol. 2007, 44: 14-17.View ArticlePubMedGoogle Scholar
- Kushima R, Hattori T: Histogenesis and characteristics of gastric-type adenocarcinomas in the stomach. J Cancer Res Clin Oncol. 1993, 120: 103-111. 10.1007/BF01200733.View ArticlePubMedGoogle Scholar
- Zea-Iriarte WL, Sekine I, Itsuno M, Makiyama K, Naito S, Nakayama T, Nishisawa-Takano JE, Hattori T: Carcinoma in gastric hyperplastic polyps: a phenotypic study. Dig Dis Sci. 2007, 44: 14-17.Google Scholar
- Chonan A, Mochizuki F, Ikeda T: Malignant transformation of hyperplastic polyp of the stomach. Gastroenterol Endosc. 1989, 31: 344-351. (in Japanese with English abstract)Google Scholar
- Ito H, Masuda H, Nakai H, Hata J, Yokosaki H, Tahara E: A study of immunohistochemical analyses of carbohydrate antigen (CA) 19-9 in gastric mucosa, adenoma, and adenocarcinoma: comparison with serum CA19-9 levels before surgery. Byori to Rinsho. 1986, 4: 1081-1088. (in Japanese)Google Scholar
- Kono M, Yamada S, Shiota G, Maeda Y, Okumura T, Miura H, Kobayashi J, Yoshimura T, Yamada M: Six cases with elevated serum CA19-9 induced by long-term administration of Sucralfate. Rinsho Kensa. 2002, 46: 929-932. (in Japanese)Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.